Literature DB >> 34918045

Hitching a ride on exosomes: a new approach for the delivery of siRNA-mediated therapies.

Allison Snyder1, Christopher Grunseich1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34918045      PMCID： PMC8677505          DOI： 10.1093/brain/awab398

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  9 in total

1.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

Review 2.  Towards precision medicine.

Authors:  Euan A Ashley
Journal:  Nat Rev Genet       Date:  2016-08-16       Impact factor: 53.242

Review 3.  Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges.

Authors:  Nicholas L Syn; Lingzhi Wang; Edward Kai-Hua Chow; Chwee Teck Lim; Boon-Cher Goh
Journal:  Trends Biotechnol       Date:  2017-03-29       Impact factor: 19.536

4.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes.

Authors:  Lydia Alvarez-Erviti; Yiqi Seow; Haifang Yin; Corinne Betts; Samira Lakhal; Matthew J A Wood
Journal:  Nat Biotechnol       Date:  2011-03-20       Impact factor: 54.908

Review 5.  Wild-type huntingtin plays a role in brain development and neuronal survival.

Authors:  Anton Reiner; Ioannis Dragatsis; Scott Zeitlin; Daniel Goldowitz
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

Review 6.  siRNA: Mechanism of action, challenges, and therapeutic approaches.

Authors:  Walhan Alshaer; Hadil Zureigat; Arwa Al Karaki; Abdulfattah Al-Kadash; Lobna Gharaibeh; Ma'mon M Hatmal; Alaa A A Aljabali; Abdalla Awidi
Journal:  Eur J Pharmacol       Date:  2021-05-24       Impact factor: 4.432

7.  Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.

Authors:  Niels H Skotte; Amber L Southwell; Michael E Østergaard; Jeffrey B Carroll; Simon C Warby; Crystal N Doty; Eugenia Petoukhov; Kuljeet Vaid; Holly Kordasiewicz; Andrew T Watt; Susan M Freier; Gene Hung; Punit P Seth; C Frank Bennett; Eric E Swayze; Michael R Hayden
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

8.  In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.

Authors:  Zheng Fu; Xiang Zhang; Xinyan Zhou; Uzair Ur-Rehman; Mengchao Yu; Hongwei Liang; Hongyuan Guo; Xu Guo; Yan Kong; Yuanyuan Su; Yangyang Ye; Xiuting Hu; Wei Cheng; Jinrong Wu; Yanbo Wang; Yayun Gu; Sheng-Feng Lu; Dianqing Wu; Ke Zen; Jing Li; Chao Yan; Chen-Yu Zhang; Xi Chen
Journal:  Cell Res       Date:  2021-03-29       Impact factor: 25.617

9.  Targeting Huntingtin Expression in Patients with Huntington's Disease.

Authors:  Sarah J Tabrizi; Blair R Leavitt; G Bernhard Landwehrmeyer; Edward J Wild; Carsten Saft; Roger A Barker; Nick F Blair; David Craufurd; Josef Priller; Hugh Rickards; Anne Rosser; Holly B Kordasiewicz; Christian Czech; Eric E Swayze; Daniel A Norris; Tiffany Baumann; Irene Gerlach; Scott A Schobel; Erika Paz; Anne V Smith; C Frank Bennett; Roger M Lane
Journal:  N Engl J Med       Date:  2019-05-06       Impact factor: 91.245
  9 in total
  1 in total

Review 1.  A Novel Perspective on Ischemic Stroke: A Review of Exosome and Noncoding RNA Studies.

Authors:  Qianwen Wang; Yuhui Chen; Lingbing Meng; Jiawen Yin; Li Wang; Tao Gong
Journal:  Brain Sci       Date:  2022-07-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.